<DOC>
	<DOCNO>NCT01673646</DOCNO>
	<brief_summary>To evaluate efficacy , safety , pharmacokinetics pharmacodynamics pasireotide LAR Japanese patient active acromegaly pituitary gigantism . Primary objective ass total-group efficacy pasireotide LAR reduction mean GH level &lt; 2.5 µg/L normalization IGF-1 3 month study treatment .</brief_summary>
	<brief_title>Efficacy Safety Pasireotide LAR Japanese Patients With Acromegaly Pituitary Gigantism</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Gigantism</mesh_term>
	<criteria>Patients medication naïve acromegaly pituitary gigantism Patients inadequately control acromegaly pituitary gigantism Diabetic patient whose blood glucose poorly control evidence HbA1c &gt; 8 % Patients congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , clinically significant bradycardia , advanced heart block history acute myocardial infarction within six month precede enrollment Patients risk factor torsade de pointes , i.e . patient baseline QTcF &gt; 470 m , hypokalemia , hypomagnesemia , hypocalcemia , family history long QT syndrome , patient receive concomitant medication know prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SOM230 , Pasireotide , acromegaly , Phase II</keyword>
</DOC>